search results for

refine results

sort by


result type


Press Releases

Allergan will repeal Restasis patent decision

CNBC's Meg Tirrell reports on the latest developments on a federal court invalidating Allergan's eye drug patents.


Allergan's Restasis patents invalidated by federal judge

CNBC's Meg Tirrell reports on Allergan sinking after a federal judge invalidates patents on their drug Restasis.


Health care stocks fall on Trump's comments

CNBC's Meg Tirrell reports on President Trump's comments on health insurers during a Cabinet meeting sending insurance stocks down.


Spark Therapeutics jumps after favorable FDA panel vote

CNBC's Meg Tirrell reports on Spark Therapeutics shares jumping after the FDA panel votes in favor of the company's gene therapy.


Baxter says minimal damage at three Puerto Rico sites

CNBC's Meg Tirrell reports on Baxter International's report of minimal damage at its Puerto Rican sites and how it's working with the FDA to support U.S. product supply.


Baxter says it expects Hurricane Maria impact on fourth-quarter revenue

But the company said it expects the impact to be mitigated by positive performance in other areas of the business.


Spark's gene therapy treatment receives 16-0 vote in favor

CNBC's Meg Tirrell reports that Spark Therapeutics has received a 16-0 vote from an FDA panel in favor of a new genetic treatment to treat a rare, inherited form of blindness


CBX: Decelerating loan growth hits bank stocks

Meg Green, Founder, Meg Green & Associates; Steve Grasso, Stuart Frankel; and CNBC's Rick Santelli discuss the day's market activity and what investors should consider.


Sparks Therapeutics' gene therapy treatment for blindness heads to FDA

CNBC's Meg Tirrell reports Sparks Therapeutics could be the first biotech company in the U.S. to get approval from the FDA to treat a rare form of blindness at its genetic root.


Health insurers, hospitals and generic-drug makers ask Congress to examine Allergan patent deal

The group is the latest to call on lawmakers to examine Allergan's controversial patent deal with a Native American tribe.